Dr. Wendy Lam, B Sc. (Pharm), MD, FRCPC
Hematologist and Medical Oncologist
Burnaby Hospital Regional Cancer Center
Director, BC Community Oncology Trialists
Dr. Wendy Lam is a hematologist and medical oncologist at the Burnaby Hospital Regional Cancer Centre.
She received her B.Sc (Pharmacy) at Dalhousie University and her MD from University of British Columbia. She then completed her Internal Medicine residency at UBC and Hematology fellowship at McMaster University.
She is the Founding Director of the British Columbia Community Oncology Trialists (BC Cot), which is a collaborative group of oncologists and hematologists involved in clinical research.
Her other interests include education of patients through meeting with patient groups. She has also been instrumental in organizing meetings for continued medical education.
She is Director of the Society of Hematology and Oncology of BC at British Columbia Medical Association
David Liu, MD, FRCP(C), FSIR, ABR(D), CAQ(IR)
University of British Columbia
Dr David M Liu MD is an Interventional Radiologist with the current appointments of Clinical Professor of Radiology at the University of British. He is board certified in both Canada and the US, and holds appointments at the Vancouver General Hospital, University of British Columbia Hospital and the BC Cancer Agency with a cross appointment in the department of Surgery. Dr Liu received his medical degree from University of Toronto, completed his radiology residency at University of British Columbia, and interventional radiology fellowship at Northwestern Memorial Hospital, and has practiced on both sides of the border. In addition to benchside and clinical research in the fields of novel embolic platforms, ablative technologies and cancer related thromboembolic disease. Dr Liu maintains an active clinical practice interventional oncology practice incorporating all aspects of embolization, ablation, venous access, and palliative therapy in all organ systems. He is the co-founder and co-chair of SHOW, and has been credited with 6 book chapters, over 50 publications, over 100 invited lecture worldwide, and is an active member and inducted fellow of the Society of Interventional Radiology. He had recently been awarded the CIRA award from the Canadian Association of Interventional Radiology (CAIR), in recognition of his extraordinary contribution to the practice of IR in Canada and worldwide. He holds specific interest in the treatment of hepatocellular carcinoma, and metastatic colorectal carcinoma and is actively involved in both translational research and clinical trials.
Dr. Jason Wong, MD, FRCPC, FSIR
Clinical Associate Professor
Cardiovascular and Interventional Radiology
Foothills Medical Centre
Cumming School of Medicine
University of Calgary
Dr. Jason Wong holds three degrees from the University of Calgary: a bachelor of science in chemistry and psychology (1994); a master of science in gastroenterology (1997); and a doctor of medicine (1999).
In 2004, he also completed residency training in diagnostic radiology at the university. As well, he become a Fellow of the Royal College of Physicians and Surgeons of Canada and was certified by the American Board of Radiology in 2004.
The following year, in 2005, Dr. Wong completed subspecialty training in interventional radiology at Stanford University’s Faculty of Medicine.
Marc Carrier, MD, MSc, FRCPC
Professor, Faculty of Medicine, University of Ottawa
Senior Scientist, Clinical Epidemiology Program, Ottawa Hospital Research Institute
Vice Chair of Research, Department of Medicine
Program Director, Thrombosis Fellowship
Marc Carrier, MD, MSc, FRCPC, is a Professor in the Faculty of Medicine, Department of Medicine, a Senior Scientist in the Clinical Epidemiology Program of The Ottawa Hospital Research Institute and Vice-Chair of Research for the Department of Medicine. He holds a Tier 2 Research Chair in Venous Thromboembolism and Cancer from the University of Ottawa and New Investigator Award from the Heart and Stroke Foundation of Canada. In 2015 he was the recipient of the prestigious Dr. Michel Chrétien Researcher of the Year Award for his study published in the New England Journal of Medicine that improves care for VTE patients around the world.
Clinical research is focused in venous thromboembolic disease and cancer, including cancer screening, prevention and management. Is currently the Principal Investigator on four peer-reviewed clinical trials (Heart and Stroke Foundation (2) and Canadian Institutes of Health Research (2) ) and numerous industry sponsored trials. He has published important systematic reviews and has had multiple international speaking invitations to speak on the topics of cancer and thrombosis.
Howard Lim, MD, PhD, FRCPC
Division of Medical Oncology, BC Cancer Agency, Vancouver Centre
Clinical Associate Professor, University of British Columbia
Chair, GI Tumor Group
Program Director, Medical Oncology Residency Training Program
Dr. Howard Lim is a Medical Oncologist with a specialty in gastrointestinal cancer at the BC Cancer Agency in Vancouver. He is currently the Program Director of the Residency Training Program and Chair of the Provincial Gastrointestinal Group. He is currently involved in the Personalized Oncogenomics Program utilizing whole genome sequencing and RNA expression technology as part of precision medicine for oncology care. He is active in clinical trials with the CCTG and is on the NCI Gastro-esophageal task force.
Jonathan Loree, MD, MS, FRCPC
University of British Columbia Medical Oncologist,
BC Cancer Vancouver, BC
Jonathan Loree is a medical oncologist at BC Cancer with an interest in GI malignancies. He completed his medical school and Internal Medicine training at the University of Alberta before completing a medical oncology fellowship at BC Cancer. He subsequently undertook a translational research fellowship at The University of Texas MD Anderson Cancer Center in Houston, Texas where he completed a Master’s of Science before returning to British Columbia. His research interests include colorectal cancer, neuroendocrine tumors, and anal cancer, with a focus on biomarker development.
Michael Overman, MD
Associate Professor, GI Medical Oncology
The University of Texas
MD Anderson Cancer Center
Michael Overman is an Associate Professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center. His research efforts have focused upon novel clinical trials in both pancreatic and intestinal cancers. In particular, he has focused upon the role of biomarker based clinical trials and the role of immune-therapy in gastrointestinal cancers. Dr. Overman has been instrumental in exploring the use of immune-therapy in the subset of patients with deficient mismatch repair.
Nicholas Fidelman, MD
Associate Professor of Clinical Radiology
University of California San Francisco
San Francisco, CA
Dr. Fidelman earned his Doctor of Medicine degree at University of California San Francisco in 2002, and completed residency in Diagnostic Radiology at UCSF in 2007 and fellowship in Vascular and Interventional Radiology at UCSF 2008.
Dr. Fidelman has been on faculty at UCSF since 2008. His clinical and research interests include liver oncology and combinations between liver-directed and systemic therapy.
Dr. Darren Klass, MBChB, MD, MRCS, FRCR, FRCPC
Clinical Associate Professor, University of British Columbia
Medical Head MRI, Vancouver General Hospital
Dr. Darren Klass is an established radiologist with extensive expertise in interventional radiology. He currently serves the people of Vancouver, British Columbia, Canada, as an Interventional Radiologist at Vancouver Coastal Health, a position he embraced in 2011. He also acts as the Medical Head of the MRI division and specializes in interventional oncology, aortic intervention, PVD, venous disease, and venous access. His subspecialties are locoregional tumor therapy, MR angiography, and treatment of venous disease. He is a world expert in transradial intervention for radiology and teaches around the world on dedicated radial courses. He performed the first transradial chemoembolization and radioembolization in Canada in 2014; the interventional radiology group at Vancouver General Hospital have collectively performed over 4000 radial procedures. Dr. Darren Klass is also an Interventional Radiologist with Vancouver Imaging, a physician-led private practice also located in Vancouver, BC. The practice provides teleradiology, subspecialist image interpretation, interventional radiology and CT/MR protocol consulting. To complement the hands-on aspects of his work, he also dedicated to his role as Clinical Associate Professor at the University of British Columbia.
Dr. Darren Klass obtained his bachelor’s degree of medicine and bachelor’s degree of surgery in South Africa from the University of Pretoria in 2001. He also obtained his doctorate from the University of East Anglia in 2011. Upon finalizing his medical education in South Africa, he continued his career with his post graduate training at Furness General Hospital in Barrow-in-Furness in the United Kingdom during his internship (2002). He additionally conducted his residency in surgery at Norfolk and Norwich University Hospitals NHS Foundation Trust in Norwich, UK in 2005, which is where he also completed his radiology residency training in 2010. Dr. Klass went on to advance his training with a fellowship in interventional radiology at the University of British Columbia in 2010. He is board certified in radiology in Canada and the United Kingdom.
Constantinos Sofocleous, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
New York, NY
Dr. Sofocleous has been a practicing interventional radiologist since 1998. He joined the Interventional Radiology Service at Memorial Sloan Kettering in 2002 where he has dedicated his career in the practice and promotion of Interventional Oncology.
Dr. Sofocleous lectures nationally and internationally on the interventional oncology therapies for cancer and especially ablation and Y90 radioembolization for liver tumors — particularly metastases from colorectal cancer. He has also lectured extensively on ablation as a treatment for primary and metastatic lung cancers. He has been a prolific author and is considered an expert on the interventional therapy of metastatic disease and especially colorectal metastases.
Dr. Sofocleous’ research interest has focused on the assessment, validation, and development of biomarkers and surrogate imaging biomarkers for interventional oncology. He has published extensively on the treatment of colorectal, neuroendocrine, and breast cancer liver metastases treated by image-guided therapies including radiofrequency and microwave ablation, irreversible electroporation, small particle bland embolization, and radio embolization/selective internal radiation therapy with Yttrium 90 microspheres.
Dr. Sofocleous was the 2016 WCIO program chair and is a director at large of the board of managers of the Society of Interventional Oncology (SIO). He serves as the international liaison of the Annual Meeting Committee of the Society of Interventional Radiology (SIR). He is a member of the NCCN panel for colon and rectal cancers. He serves as editorial board member for interventional oncology for the journal of Cardiovascular and Interventional Radiology (CVIR) and the International Journal of Hyperthermia. He is a reviewer for several journals including Radiology, JVIR, CVIR, Annals of Surgical Oncology, Journal of National Comprehensive Cancer Network, Hepatology, Oncotarget and others. He has delivered over 300 invited presentations/lectures and has been an author in over 149 peer-reviewed manuscripts.
Shyam M. Srinivas, M.D., Ph.D., FACNM
Deputy Director of PET/CT Research and Clinical Instructor
Division of Nuclear Medicine and Molecular Imaging
Department of Radiology, Stanford University
Dr. Srinivas is a research-oriented Nuclear Medicine physician-scientist who completed both M.D. and Ph.D. degrees at the University of California, Irvine in 2002. He completed his residency training in Nuclear Medicine in 2006 at the University of Pennsylvania in Philadelphia, PA after a preliminary year of internal medicine internship at Christina Care in Newark, DE. Dr. Srinivas then joined the Cleveland Clinic Department of Nuclear Medicine in 2006 where he served as the Vice-Chairman of Nuclear Medicine since 2011. In 2016, he joined the faculty at Stanford University as a Clinical Instructor and the Deputy Director of PET/CT Research in the Division of Nuclear Medicine and Molecular Imaging. His most recent position in 2017 is as the Chief Medical Officer for Sirtex Medical Inc., the world’s largest supplier of Y-90 radiomicrospheres for radioembolization.
Dr. Srinivas has been involved in numerous patient oriented clinical trials with novel radiotracers and therapeutic radioisotopes, either as Principal Investigator or a Co-Investigator over the years. His research interests include PET/CT & PET/MR imaging, dosimetry, novel tracers, and radioisotope therapy.
Joseph Amaral, MD, FACS
Vice President of Surgical Sciences (Chief Scientific Officer)
Energy Unit of Johnson and Johnson Corporation
Dr. Joseph F Amaral (Dr. Joe) is Vice President of Surgical Sciences (Chief Scientific Officer) for the Energy Unit of Johnson and Johnson Corporation. In this role, he is responsible for developing deeper scientific and clinical insights of energy-based technologies that will lead to more meaningful innovation and safer application of these technologies that will improve patient care.
Most recently, Dr. Amaral was Vice President of Medical Devices and Diagnostics Emerging Technologies for Johnson and Johnson Corporation. In this role, he provided scientific leadership to the MD&D sector of Johnson and Johnson Corporation by identifying sustaining, disruptive and/or white space science and technology opportunities of strategic relevance; provides context, and perspective to MD&D companies on arenas of emerging science and technology; and ensures access to game changing science and technology in areas of strategic relevance to MD&D.
Prior to that he was President and CEO of Rhode Island Hospital (RIH) and its pediatric division Hasbro Children’s Hospital from 2000 to 2007 and served as its COO for 3 1/2 years. This is the state of Rhode Island’s largest private employer, Brown University’s largest teaching affiliate, and the third largest hospital in New England. During this period, he led a financial turnaround while at the same time investing over $450 million in renovation projects, new technologies and new facilities and tripling externally funded research.
He is internationally recognized as a pioneer in laparoscopic (minimally invasive) surgery. He introduced these approaches to Rhode Island and New England in 1990. He has performed approximately 3,000 laparoscopic procedures and trained hundreds of practicing surgeons in these techniques throughout New England, broadly across the U.S., and around the world. He has operated in 20 countries and on five continents.
Dr. Amaral was instrumental in the success of UltraCision, a startup company, by developing with company CEO Tom Davison, Ph.D., the Harmonic Scalpel, the first and still leading ultrasonically activated cutting and coagulating surgical device. He has served as a consultant, advisory board member and board member to multiple leading healthcare biotech and startup companies.
He is Professor of Surgery (Emeritus) at Brown University School of Medicine, member of 25+ professional societies, author of 80+ papers and book chapters and has delivered 250+ national and international presentations. Prior to becoming RIH President and CEO, Dr. Amaral was Chairman of the Department of Surgery at Brown University School of Medicine, Chief of Surgery at Rhode Island Hospital, President of University Surgical Associates and Executive Chief of Surgery at Lifespan Affiliated Hospitals
He graduated summa cum laude in 1977 from Providence College, obtained his MD degree from Brown Medical School in 1981 and completed his surgical residency training at Brown University/Rhode Island Hospital in 1989.
Sean P. Cleary, MD, FACS
Associate Professor of Surgery
Mayo Clinic College of Medicine and Science
Sean P. Cleary, M.D., is a consultant in the Division of Hepatobiliary and Pancreas Surgery, Department of Surgery at Mayo Clinic in Rochester, Minnesota. Dr. Cleary holds the academic rank of Associate Professor of Surgery, Mayo Clinic College of Medicine and Science.
Dr. Cleary earned his B.Sc. with honors at Queens University in Kingston, Ontario, and his M.D. at the University of Western Ontario in London, Ontario. He completed a residency in general surgery at the University of Toronto, where he also completed the Clinical Investigator Program earning his Master of Science degree. He continued his training at the University of Toronto, completing a fellowship pin hepatobiliary oncology and transplantation surgery and earning his Master of Public Health in community health and epidemiology.
Dr. Cleary served on the staff of University Health Network at the University of Toronto prior to joining Mayo Clinic in March 2017. His clinical interests include the surgical treatment of pancreatic, hepatic and biliary malignancies with a specific focus on minimally invasive approaches to these cancers. His research interests include the genetic epidemiology of pancreatic and hepatocellular cancers. He is frequently invited to give presentations on his work to both national and international audiences and has authored numerous journal articles, book chapters, abstracts and other written publications. He also serves as associate editor of BMC Cancer and holds reviewer responsibilities for prominent scientific publications.
In addition to his clinical and research activities, Dr. Cleary is active in education and has provided mentorship to many residents and fellows, among others. He is a recipient of the Frank Milles Teaching Award and Nicolas Colapinto Teaching Award, conferred by the University of Toronto.
Dr. Cleary is a fellow of the American College of Surgeons and was recently elected to the Board of Governors as the Surgical Specialty Society Governor from the Canadian Association of General Surgeons. He is a member of professional organizations, including American Hepato-Pancreato-Biliary Association, Canadian Association for General Surgeons, Society for Surgery of the Alimentary Tract, where he has served on many committees and in leadership roles.
Paul Hansen, MD, FACS
Medical Director, Surgical Oncology
Program Director, Liver and Pancreas Surgery
Portland Providence Cancer Center
Paul D. Hansen, M.D. completed medical school at the University of Washington School of Medicine, and residency in general surgery at the University of California – San Francisco. Dr. Hansen went on to complete fellowships in Hepatobiliary and Pancreatic Surgery at the Royal College of Medicine at Hammersmith Hospital in London, England, and in Laparoscopy and Surgical Endoscopy at Legacy Portland Hospitals/Oregon Health and Science University in Portland, Oregon.
Dr. Hansen has helped to pioneer minimally invasive surgical approaches to liver and pancreatic cancers, and has advanced research in laparoscopic liver tumor ablation (RFA), as well as laparoscopic-assisted liver chemotherapy, including laparoscopic chemotherapy pump placement, and laparoscopic assisted chemo-embolization.
Dr. Hansen has more than 80 peer reviewed publications and is actively involved in many surgical societies such as the American Hepato-Pancreato-Biliary Society, Society of Surgical Oncologists, Society of American Gastrointestinal Endoscopic Surgeons, Society for Surgeons of the Alimentary Tract, Pacific Coast Surgical, the American College of Surgeons, and Portland Surgical Society. Dr. Hansen annually volunteers for overseas medical missions to countries such as Pakistan, Guatemala, Vietnam, and Cambodia.
Peter Kim, MD, MSc, FRCSC, FACS
Clinical Associate Professor
University of British Columbia
Surgeon, Vancouver General Hospital
Dr. Peter Kim is a liver transplant and a hepatopancreatobiliary (HPB) surgeon at the Vancouver General Hospital. He is a associate clinical professor of the Department of Surgery, University of British Columbia.
Dr. Kim received his medical degree from the University of Western Ontario in London, Ontario, Canada. He completed his general surgery residency and Masters of Sciences degree at the University of British Columbia. His research work focused on differentiating embryonic stem cells into insulin producing cells to treat diabetes. He subsequently completed his abdominal transplant surgery fellowship at Baylor University Medical Center, Dallas, Texas, followed by a living donor liver transplantation/HPB surgery fellowship at the University of Toronto.
After his training, Dr. Kim worked at the Baylor University Medical Center as the assistant director of living donor liver transplantation for 5 years before returning to the Vancouver General Hospital to join the liver transplantation team. His clinical practice includes liver transplantation and hepatopancreatobiliary surgery.
Dr. Kim is an author of over 50 publications and 7 book chapters. His research interests include studying the importance of blood flow to the liver in liver transplantation, bile duct complications in liver transplantation and complex surgical resections in pancreas cancer surgery.
Ian D. McGilvray, MD, PhD, FRCSC
Associate Professor of Surgery, University of Toronto
HBP & Multi Organ Transplant Program
Toronto General Hospital, University Health Network
Dr McGilvray studied medicine at McGill University, graduating in 1993. He entered the General Surgery training program at the University of Toronto that same year. During his residency he undertook graduate studies in Dr. Ori Rotstein’s laboratory, and obtained a PhD in Cell Biology. He became a Fellow of the Royal College of Physicians and Surgeons of Canada in 2001. After a clinical fellowship in Transplantation and Hepatobiliary Surgery at Toronto General Hospital, he began his appointment at University Health Network in 2003. He is currently an Associate Professor in the Department of Surgery at the University of Toronto. His clinical focus is devoted to transplantation, with an interest in complex hepatobiliary oncology. His research centers on diseases of the liver, particularly hepatitis C viral infection.
Laura Dawson, MD, FRCPC, FASTRO
Department of Radiation Oncology
University of Toronto
Laura Dawson is a radiation oncologist at the Princess Margaret Cancer Centre, and a Professor the Department of Radiation Oncology, University of Toronto. She is an internationally recognized leader in hepatobiliary cancers, oligo-metastases and in the use of advanced radiation technologies, including stereotactic body radiation therapy (SBRT). She is presently the principal investigator of RTOG1112, an international phase III randomized trial of SBRT for locally advanced hepatocellular carcinoma, and HE.1, a Canadian phase III randomized trial of low dose whole liver radiation therapy to treat painful primary and metastatic liver cancers. She has published over 180 scientific papers, and has received numerous awards for her teaching and research.
Andrew Kennedy, MD
Physician in Chief, Radiation Oncology
Director, Radiation Oncology Research
Sarah Cannon Research Institute
Dr. Kennedy joined Sarah Cannon in 2012 as the Physician in Chief, Radiation Oncology and Director, Radiation Oncology Research at Sarah Cannon Research Institute where he is responsible for strategic development of radiation oncology services for HCA Healthcare and development of radiation oncology research program within Sarah Cannon to complement the world-class medical oncology program. Dr. Kennedy is a graduate of the Loma Linda School of Medicine in California, and completed his residency at The University of North Carolina at Chapel Hill.
He is an internationally renowned radiation oncologist specializing in gastrointestinal cancers, as well as cancers of the breast and lung. Nationally, he served as a member of the Board of Chancellors for the American College of Radiation Oncology and is a Fellow of the College. He has been selected yearly since 2009 as one of America’s Best Doctors (top 5 percent of U.S.), and was inducted into Alpha Omega Alpha (AOA) Honor Society as a faculty member in 1999.
E. Celia Marginean, MD, FRCPC, FCAP
Professor of Pathology, University of Ottawa
Head, Gastrointestinal Pathology Section
Deputy Director Section of Cytopathology
The Ottawa Hospital
Dr. Marginean is a Full Professor of Pathology at Ottawa University.
She has a number of local, provincial and national leadership roles: Head of GI Pathology Section and Deputy Head of Cytopathology Section at Ottawa Hospital; She is part of several committees: Canadian Partnership Against Cancer , GI Endoscopy Steering Committee Champlain LHIN, Communities of Practice Champlain LHIN (thyroid, colorectal), US and Canadian Academy of Pathologists, Commonwealth Neuroendocrine Tumour Group.
She is the current president of Ontario Association of Pathologists.
The majority of her research projects are related to biomarkers in cancer, and were presented at local, national or international meetings and published in high impact peer-reviewed journals